Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$37.27
-$0.34(-3.65%)
At close: 4:00 PM EST
$37.27
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$12.25 - $40.22
Previous CloseN/A
Volume337.58K
Average Volume (3M)874.44K
Market Cap
$1.81B
Enterprise Value$1.71K
Total Cash (Recent Filing)$343.55M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 10, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume637,740
30 Day Avg. Volume874,436
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$47.29Price Target Upside26.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.29
Revenue Forecast (FY)$27.67M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetNear-zero debt and a sizable equity base provide durable financial flexibility to fund clinical programs, negotiate partnerships, or weather development delays without immediate refinancing. This reduces bankruptcy risk and preserves strategic optionality over the next 2–6 months.
Phase 3 Enrollment Complete; Regulatory Path DefinedFull enrollment and a stated plan for a rolling NDA materially de‑risks the lead program and creates a clear regulatory pathway. This structural progress increases the likelihood of a defined data timeline and potential approval discussions, strengthening long‑term commercial prospects.
High Gross Profitability When Revenue PresentSustained high gross margins indicate favorable product economics for the ASO platform, implying scalable unit economics if commercialization is achieved. Durable margin potential can translate into attractive long‑term profitability once fixed R&D and SG&A are aligned with revenue.
Bears Say
Sharp Revenue Decline And Large Negative MarginsAn ~82% TTM revenue collapse and deeply negative net margins reflect weak commercial or partnership receipts and magnify the fixed‑cost burden. Absent near‑term revenue recovery or milestone receipts, losses will persist and hinder sustainable operations over the medium term.
Elevated Operating Cash Burn And Negative Free Cash FlowLarge negative operating and free cash flows signal heavy funding needs to continue development. This increases dependence on financing or partner deals, risks diluting shareholders, and constrains the firm’s ability to advance multiple programs simultaneously over coming quarters.
Persistent Losses And Negative Return On EquityA materially negative ROE highlights continued operating losses that erode shareholder value and signal weak capital efficiency. Sustained negative returns reduce attractiveness to investors and may pressure management to pursue dilutive financing or partnerships to sustain development.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was $12.25 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $1.81B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 20 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on May 07, 2026. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.808 by $0.018.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.8.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 62,281,654 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.808. Following the earnings report the stock price went up 0.305%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.29 (26.87% Upside)
$47.29 (26.87% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 41.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
135.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.94%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Stock 12 Month Forecast
Average Price Target
$47.29
▲(26.87% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
28.38% Insiders
20.88% Mutual Funds
1.90% Other Institutional Investors
33.16% Public Companies and
Individual Investors